Resource Summary Report

Generated by dkNET on Sep 2, 2026

SK-MEL-5

RRID:CVCL_0527
Type: Cell Line

Proper Citation

RRID:CVCL_0527

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0527

Proper Citation: RRID:CVCL_0527

Description: Cell line SK-MEL-5 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Cutaneous melanoma

Defining Citation: PMID:313568, PMID:327080, PMID:833871, PMID:1067619, PMID:2041050, PMID:3335022, PMID:3518877, PMID:7017212, PMID:7718330, PMID:7747814, PMID:7999427, PMID:8631022, PMID:9331090, PMID:10700174, PMID:11016658, PMID:14871852, PMID:15299072, PMID:15467732, PMID:15748285, PMID:17088437, PMID:17363583, PMID:17516929, PMID:19372543, PMID:20164919, PMID:21725359, PMID:22068913, PMID:22347499, PMID:22384151, PMID:22460905, PMID:22628656, PMID:23856246, PMID:23933261, PMID:24279929, PMID:24576830, PMID:24670534, PMID:25485619, PMID:25960936, PMID:25984343, PMID:26589293, PMID:27377824, PMID:27397505, PMID:27600516, PMID:27807467, PMID:28196595, PMID:30894373, PMID:31068700, PMID:31733513, PMID:31978347, PMID:35839778, PMID:38861359

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SK-MEL-5

Synonyms: SK-Mel-5, SK MEL 5, SK.MEL.5, SK-MEL5, SKMel-5, SKMEL-5, SKMEL5, SKMel5, SKmel5, AA-Mel

Cross References: BTO:BTO_0002134, CLO:CLO_0009047, EFO:EFO_0005720, MCCL:MCC:0000427, CLDB:cl7123, 4DN:4DNSRTEP2XSG, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-70, BioSample:SAMN03472753, BioSample:SAMN10988351, cancercelllines:CVCL_0527, CancerTools:161920, Cell_Model_Passport:SIDM00080, CGH-DB:9316-4, ChEMBL-Cells:CHEMBL3307744, ChEMBL-Targets:CHEMBL614922, CLS:300157, Cosmic:686475, Cosmic:688055, Cosmic:875886, Cosmic:905229, Cosmic:905956, Cosmic:932996, Cosmic:974074, Cosmic:974258, Cosmic:1022282, Cosmic:1092634, Cosmic:1132588, Cosmic:1175873, Cosmic:1247851, Cosmic:1303057, Cosmic:1305369, Cosmic:1312351, Cosmic:1458967, Cosmic:1459648, Cosmic:1477410, Cosmic:1481415, Cosmic:1507626, Cosmic:1669130, Cosmic:1998477, Cosmic:2159434, Cosmic:2479253, Cosmic-CLP:905956, DepMap:ACH-000730, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS029HXQ, ENCODE:ENCBS324XRL, ENCODE:ENCBS398HNX, ENCODE:ENCBS465YNJ, ENCODE:ENCBS518AAA, ENCODE:ENCBS519AAA, ENCODE:ENCBS524EJL, ENCODE:ENCBS697RNA, ENCODE:ENCBS981ZNI, GDSC:905956, GEO:GSM2094, GEO:GSM50206, GEO:GSM50268, GEO:GSM171011, GEO:GSM188227, GEO:GSM188257, GEO:GSM188316, GEO:GSM226866, GEO:GSM743469, GEO:GSM750826, GEO:GSM799358, GEO:GSM799421, GEO:GSM844691, GEO:GSM847117, GEO:GSM887589, GEO:GSM888672, GEO:GSM1138791, GEO:GSM1153429, GEO:GSM1181267, GEO:GSM1181310, GEO:GSM1670443, GEO:GSM2124683, IARC_TP53:21090, ICLC:HTL01023, KCLB:30070, LiGeA:CCLE_242, LINCS_LDP:LCL-1282, Lonza:1202, NCI-DTP:SK-MEL-5, PharmacoDB:SKMEL5_1400_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_0527, PubChem_Cell_line:CVCL_0527, SKY/M-FISH/CGH:2821, Wikidata:Q54954250

ID: CVCL_0527

Record Creation Time: 20220427T221546+0000

Record Last Update: 20260829T235931+0000

Ratings and Alerts

No rating or validation information has been found for SK-MEL-5.

No alerts have been found for SK-MEL-5.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 260 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Cobb DA, et al. (2026) ?v?3 CAR-T Cells Simultaneously Targeting Tumor and Metastases Produce Highly Effective Control in Preclinical Models of Melanoma and Triple-Negative Breast Cancer. Molecular cancer therapeutics, 25(7), 1181.

O'Loughlin TA, et al. (2026) mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway. Molecular cell, 86(8), 1546.

Chen K, et al. (2026) Amino acid supplementation enhances in vivo efficacy of lipid nanoparticle-mediated mRNA delivery in preclinical models. Science translational medicine, 18(840), eadx4097.

Shi HZ, et al. (2026) BGN/MDK Axis in the Melanoma Tumor Microenvironment Strengthens Tumor Malignancy by Modulating Cancer Cells and Cancer-Associated Fibroblasts Crosstalk. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(28), e14590.

Takeda S, et al. (2026) A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells. Cancer research, 86(8), 2024.

Alaimo A, et al. (2025) TRPM8 levels determine tumor vulnerability to channel agonists. Molecular oncology.

Moore SPG, et al. (2025) PAX3 Regulatory Signatures and Gene Targets in Melanoma Cells. Genes, 16(5).

Boucher J, et al. (2025) CDK12 inhibition reveals melanoma dependence on the RUNX1/CBF? complex for genomic stability. Cell reports, 44(11), 116495.

Degefu YN, et al. (2025) Cell state plasticity emerging from co-regulated, competitive, and configurable interactions within the AP-1 network. bioRxiv : the preprint server for biology.

Abrantes R, et al. (2025) Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors. Cell reports. Medicine, 6(9), 102350.

Weller C, et al. (2025) Translation dysregulation in cancer as a source for targetable antigens. Cancer cell, 43(5), 823.

Gadal S, et al. (2025) Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration. Cancer research, 85(9), 1611.

Ma X, et al. (2024) TRPM7 controls skin keratinocyte senescence by targeting intracellular calcium signaling. The FEBS journal, 291(21), 4680.

Cai C, et al. (2024) NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth. Molecular cancer research : MCR, 22(4), 386.

Ling H, et al. (2024) HDAC10 inhibition represses melanoma cell growth and BRAF inhibitor resistance via upregulating SPARC expression. NAR cancer, 6(2), zcae018.

Mondru AK, et al. (2024) The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib. FEBS letters, 598(16), 2011.

Dairo O, et al. (2024) FASN Gene Methylation is Associated with Fatty Acid Synthase Expression and Clinical-genomic Features of Prostate Cancer. Cancer research communications, 4(1), 152.

Wang Z, et al. (2024) Phenotypic targeting using magnetic nanoparticles for rapid characterization of cellular proliferation regulators. Science advances, 10(19), eadj1468.

Tubita A, et al. (2024) Latent-Transforming Growth Factor ?-Binding Protein 1/Transforming Growth Factor ?1 Complex Drives Antitumoral Effects upon ERK5 Targeting in Melanoma. The American journal of pathology, 194(8), 1581.

Delaunay T, et al. (2024) Exogenous non-coding dsDNA-dependent trans-activation of phagocytes augments anti-tumor immunity. Cell reports. Medicine, 5(5), 101528.